FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

Researchers explore brain cancer vaccine

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!


Researchers are touting the early results from a study of a new brain cancer vaccine that combines protein antigens extracted from a patient's tumor and matches them with white cells also drawn from the patient. The therapy is injected into patients, spurring T-cells to attack the remaining cancer cells after tumor-removal surgery. The vaccine, DCVax-Brain, is being developed by Bothell, WA-based Northwest Biotherapeutics.

"I've never seen a clinical trial that's had this promise," said Dr. Michael Gruber, medical director of the Brain Tumor Center of New Jersey.

- read the article from the Monterey Herald

Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:
Be the first to comment
More stories about Vaccine   brain cancer   DCVax-Brain   Northwest Biotherapeutics  


Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

This question is for testing whether you are a human visitor and to prevent automated spam submissions.